Full Press Release Details
MediciNova Reports Fourth Quarter and Full Year 2012 Results
SAN DIEGO, Calif. March 28, 2013 MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Trading Symbol:
MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2012.
A detailed discussion of financial results and product development programs can be found in MediciNova s Annual Report on Form 10-K for the year ended December 31, 2012, which was filed
with the Securities and Exchange Commission on March 28, 2013 and is available through investors.medicinova.com/sec.cfm.
For the quarter ended
December 31, 2012, MediciNova reported a net loss of $2.4 million, or $0.14 per share, compared to a net loss of $3.5 million, or $0.22 per share, for the same period last year. For the quarter ended December 31, 2012, service revenue
relating to the Kissei services agreement was approximately $40,000. There were no revenues for the quarter ended December 31, 2011. Research and development expenses were $0.8 million for the quarter ended December 31, 2012, as compared
to $1.4 million for the quarter ended December 31, 2011. The decrease in research and development expenses was due primarily to a decrease in spending on MN-221 resulting from the completion of the MN-221-CL-007 trial in patients with acute
exacerbations of asthma, partially offset by an increase in spending on our MN-221-CL-012 and MN-166 clinical trials. General and administrative expenses were $1.7 million for the quarter ended December 31, 2012, as compared to $2.1 million for
the quarter ended December 31, 2011. The decrease in general and administrative expenses was due primarily to a decrease in employee compensation expense including stock-based compensation.
At December 31, 2012, we had available cash and cash equivalents of $4.0 million and working capital of $3.4 million. The Company will require
additional cash funding to continue to execute its strategic plan and fund operations through December 31, 2013. These factors raise substantial doubt about the Company s ability to continue as a going concern. Between August 21, 2012
and today s date, we have generated proceeds of $3.0 million under the Common Stock Purchase Agreement with Aspire Capital Fund LLC ( Aspire ) including proceeds of $1.5 million subsequent to December 31, 2012. We have the right,
subject to the terms of this agreement, to cause Aspire to acquire up to 3,231,096 shares for total gross proceeds not to exceed $20 million (including 2,019,696 shares issued or sold to Aspire to date for the $3.0 million). We expect to sell
additional shares under this agreement during 2013 and we are also pursuing other opportunities to raise capital.
Recent Highlights in 2013
This past year has been very productive for MediciNova as we have substantially increased the breadth
of our MN-166 development program in opioid dependence and methamphetamine dependence and defined an approval pathway for MN-221. Building on this in 2013 we expect to expand the clinical development of MN-166 with grant-aided support and seek
strategic partnership to continue the development progress of MN-221. We believe our continued focus on partnering with leading clinical developers provides our shareholders with very attractive leverage on the capital they have invested in
us, said Yuichi Iwaki, M.D., Ph.D, President and Chief Executive Officer of MediciNova, Inc.
MediciNova, Inc. is a publicly traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet need with a commercial focus on the U.S. market. MediciNova s current strategy is to focus on its prioritized product candidate, MN-166 (ibudilast) for neurological disorders. MN-166 is being developed in Phase 1 and
Phase 2 clinical trials for drug dependence and pain, largely through investigator sponsored trials and outside funding. Proceeding with proof-of-concept Phase 2b trial(s) in Progressive MS is dependent on receipt of funding, which we are
pursuing. MediciNova is engaged in strategic partnering and consortium funding discussions to support further development of the ibudilast/MN-166 program and to continue the development progress of MN-221 for the treatment of acute
exacerbations of asthma. For more information on MediciNova, Inc., please visit www.medicinova.com.
Statements in this press release that
are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements
regarding our clinical development strategies, including future development, statements regarding the progress of clinical trials, statements regarding expectations for the ibudilast/MN-166 program, including development of ibudilast/MN-166 for
certain indications and expectations on future progress in the development of our drug candidates, expected timing of clinical trial results and any implication as to the results of our development, partnering and funding efforts, the implication of
patent terms and potential product exclusivity and the implication that the company will have the ability to execute on its priorities. These forward-looking statements may be preceded by, followed by or otherwise include the words
believes, expects, anticipates, intends, estimates, projects, can, could, may, will, would, or similar expressions.
These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or
events to differ materially from those expressed or implied by these forward-looking statements, include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-221 and risks of raising sufficient
capital when needed to fund MediciNova s
operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials
designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later
stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product
candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected,
the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing
of expected filings with the regulatory authorities, MediciNova s collaborations with third parties, the availability of funds to complete product development plans and MediciNova s ability to obtain third party funding for programs and
raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2011 and
its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these
forward-looking statements.
Chief Business Officer
Continuum Health Communications
CONSOLIDATED BALANCE SHEETS
| December 31, | ||||||||
| 2012 | 2011 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 4,010,530 | $ | 15,093,124 | ||||
| Prepaid expenses and other current assets | 411,592 | 614,540 | ||||||
| Total current assets | 4,422,122 | 15,707,664 | ||||||
| Goodwill | 9,600,241 | 9,600,241 | ||||||
| In-process research and development | 4,800,000 | 4,800,000 | ||||||
| Investment in joint venture | 667,204 | 650,000 | ||||||
| Property and equipment, net | 78,474 | 29,425 | ||||||
| Total assets | $ | 19,568,041 | $ | 30,787,330 | ||||
| Liabilities and Stockholders Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 491,853 | $ | 718,882 | ||||
| Accrued expenses | 314,652 | 1,515,815 | ||||||
| Accrued compensation and related expenses | 228,124 | 599,087 | ||||||
| Current deferred revenue | 3,163 | 863,510 | ||||||
| Total current liabilities | 1,037,792 | 3,697,294 | ||||||
| Deferred tax liability | 1,956,000 | 1,956,000 | ||||||
| Long-term deferred revenue | 1,694,257 | 1,636,490 | ||||||
| Total liabilities | 4,688,049 | 7,289,784 | ||||||
| Stockholders equity: | ||||||||
| Preferred stock, $0.01 par value; 3,000,000 and 500,000 shares authorized at December 31, 2012 and December 31, 2011; 220,000 shares issued at December 31, 2012 and December 31, 2011 | 2,200 | 2,200 | ||||||
| Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized at December 31, 2012 and December 31, 2011; 17,407,311 and 16,127,615 shares issued at December 31, 2012 and December 31, 2011, respectively, and 17,403,125 and 16,088,015 shares outstanding at December 31, 2012 and December 31, 2011, respectively | 17,407 | 16,128 | ||||||
| Additional paid-in capital | 312,293,225 | 309,998,251 | ||||||
| Accumulated other comprehensive loss | (67,957 | ) | (56,845 | ) | ||||
| Treasury stock, at cost; 4,186 shares at December 31, 2012 and 39,600 shares at December 31, 2011 | (1,131,086 | ) | (1,189,705 (1,197,935 | ) ) | ||||
| Deficit accumulated during the development stage | (296,233,797 | ) | (285,272,483 | ) | ||||
| Total stockholders equity | 14,879,992 | 23,497,546 | ||||||
| Total liabilities and stockholders equity | $ | 19,568,041 | $ | 30,787,330 |
CONSOLIDATED STATEMENTS OF OPERATIONS
| Years ended December 31, | Period from September 26, 2000 (inception) to December 31, 2012 | |||||||||||
| 2012 | 2011 | |||||||||||
| Revenues | $ | 802,580 | $ | $ | 2,360,807 | |||||||
| Operating expenses: | ||||||||||||
| Cost of revenues | 1,258,421 | |||||||||||
| Research and development | 5,013,092 | 7,784,719 | 167,054,655 | |||||||||
| General and administrative | 6,734,844 | 8,323,715 | 112,257,368 | |||||||||
| Total operating expenses | 11,747,936 | 16,108,434 | 280,570,444 | |||||||||
| Operating loss | (10,945,356 | ) | (16,108,434 | ) | (278,209,637 | ) | ||||||
| Impairment charge on investment securities | (1,735,212 | ) | ||||||||||
| Other expense | (29,605 | ) | (81,292 | ) | (389,230 | ) | ||||||
| Interest expense | (1,595,093 | ) | (3,605,818 | ) | ||||||||
| Other income | 24,791 | 62,316 | 19,145,183 | |||||||||
| Loss before income taxes | (10,950,170 | ) | (17,722,503 | ) | (264,794,714 | ) | ||||||
| Income taxes | (11,144 | ) | (11,573 | ) | (75,961 | ) | ||||||
| Net loss | (10,961,314 | ) | (17,734,076 | ) | (264,870,675 | ) | ||||||
| Accretion to redemption value of redeemable convertible preferred stock | (98,445 | ) | ||||||||||
| Deemed dividend resulting from beneficial conversion feature on Series C redeemable convertible preferred stock | (31,264,677 | ) | ||||||||||
| Net loss applicable to common stockholders | (10,961,314 | ) | $ | (17,734,076 | ) | $ | (296,233,797 | ) | ||||
| Basic and diluted net loss per common share | $ | (0.66 | ) | $ | (1.20 | ) | ||||||
| Shares used to compute basic and diluted net loss per share | 17,261,821 | 14,813,156 | ||||||||||
| Net loss applicable to common stockholders | $ | (10,961,314 | ) | $ | (17,734,076 | ) | $ | (296,233,797 | ) | |||
| Other comprehensive loss, net of tax: | ||||||||||||
| Foreign currency translation adjustments | (11,112 | ) | (1,143 | ) | (67,957 | ) | ||||||
| Comprehensive loss | $ | (10,972,426 | ) | $ | (17,735,219 | ) | $ | (296,301,754 | ) |